Susquehanna International Group
EDIT icon

Susquehanna International Group’s Editas Medicine EDIT Stock Holding History

Susquehanna International Group’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$482K Buy
195,100
+160,100
+457% +$339K ﹤0.01% 9773
2025
Q4 		$71.8K Sell
35,000
-44,200
-56% -$128K ﹤0.01% 11618
2025
Q3 		$275K Buy
79,200
+5,100
+7% +$14.2K ﹤0.01% 10313
2025
Q2 		$163K Sell
74,100
-76,000
-51% -$124K ﹤0.01% 11428
2025
Q1 		$174K Buy
150,100
+115,500
+334% +$170K ﹤0.01% 11085
2024
Q4 		$43.9K Sell
34,600
-14,400
-29% -$36.7K ﹤0.01% 11730
2024
Q3 		$167K Sell
49,000
-21,200
-30% -$92.3K ﹤0.01% 10640
2024
Q2 		$328K Sell
70,200
-206,800
-75% -$1.17M ﹤0.01% 9243
2024
Q1 		$2.06M Sell
277,000
-121,800
-31% -$1.01M ﹤0.01% 5270
2023
Q4 		$4.04M Buy
398,800
+274,700
+221% +$2.41M ﹤0.01% 4082
2023
Q3 		$968K Sell
124,100
-10,000
-7% -$85.8K ﹤0.01% 6698
2023
Q2 		$1.1M Buy
134,100
+54,100
+68% +$471K ﹤0.01% 6455
2023
Q1 		$580K Sell
80,000
-164,000
-67% -$1.46M ﹤0.01% 8211
2022
Q4 		$2.16M Buy
244,000
+51,800
+27% +$569K ﹤0.01% 4552
2022
Q3 		$2.35M Buy
192,200
+122,700
+177% +$1.91M ﹤0.01% 4603
2022
Q2 		$822K Buy
69,500
+6,700
+11% +$89.8K ﹤0.01% 7013
2022
Q1 		$1.19M Sell
62,800
-31,700
-34% -$589K ﹤0.01% 6668
2021
Q4 		$2.51M Sell
94,500
-355,600
-79% -$12.2M ﹤0.01% 4993
2021
Q3 		$18.5M Buy
450,100
+88,200
+24% +$4.83M ﹤0.01% 2059
2021
Q2 		$20.5M Buy
361,900
+3,300
+0.9% +$122K ﹤0.01% 1994
2021
Q1 		$15.1M Sell
358,600
-144,200
-29% -$8.21M ﹤0.01% 2231
2020
Q4 		$35.3M Buy
502,800
+373,000
+287% +$15.3M 0.01% 1236
2020
Q3 		$3.64M Buy
129,800
+8,200
+7% +$267K ﹤0.01% 3546
2020
Q2 		$3.6M Buy
121,600
+67,600
+125% +$1.77M ﹤0.01% 3502
2020
Q1 		$1.07M Buy
54,000
+11,300
+26% +$285K ﹤0.01% 5246
2019
Q4 		$1.26M Sell
42,700
-52,800
-55% -$1.32M ﹤0.01% 5077
2019
Q3 		$2.17M Buy
95,500
+6,900
+8% +$171K ﹤0.01% 4023
2019
Q2 		$2.19M Sell
88,600
-14,500
-14% -$346K ﹤0.01% 3986
2019
Q1 		$2.52M Buy
103,100
+19,000
+23% +$430K ﹤0.01% 3406
2018
Q4 		$1.91M Sell
84,100
-88,300
-51% -$2.4M ﹤0.01% 3591
2018
Q3 		$5.49M Sell
172,400
-122,600
-42% -$3.96M ﹤0.01% 2579
2018
Q2 		$10.6M Sell
295,000
-76,400
-21% -$2.71M ﹤0.01% 1877
2018
Q1 		$12.3M Buy
371,400
+127,800
+52% +$4.55M ﹤0.01% 1604
2017
Q4 		$7.49M Buy
243,600
+66,200
+37% +$1.67M ﹤0.01% 2096
2017
Q3 		$4.26M Sell
177,400
-60,200
-25% -$1.15M ﹤0.01% 2712
2017
Q2 		$3.99M Buy
237,600
+190,900
+409% +$3.44M ﹤0.01% 2706
2017
Q1 		$1.04M Buy
46,700
+32,500
+229% +$674K ﹤0.01% 5041
2016
Q4 		$230K Buy
+14,200
New +$215K ﹤0.01% 8440

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group's EDIT Position: Q1 2026 in Review

Susquehanna International Group reduced its Editas Medicine (EDIT) stake by 90% in Q1 2026, selling an estimated $1.34M and leaving 73,105 shares worth $181K. The position accounts for ﹤0.01% of the portfolio, ranked #11800.

Susquehanna International Group first reported a position in EDIT in Q4 2016 and has held it in 37 quarters since. The position peaked at $18.6M in Q2 2021. 208 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

  • Susquehanna International Group held 73,105 shares of Editas Medicine worth $181K as of Q1 2026.
  • Susquehanna International Group sold 631,557 Editas Medicine shares in Q1 2026, an estimated $1.34M.
  • Editas Medicine made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11800 holding.
  • Susquehanna International Group first reported a position in Editas Medicine in Q4 2016 and has held it in 37 quarters since.
  • Susquehanna International Group's Editas Medicine position peaked at $18.6M in Q2 2021.
  • 208 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.